Welcome to the e-CCO Library!

DOP83: Proactive dosing is superior to clinically based dosing in terms of endoscopic healing in paediatric patients with Crohn's disease receiving maintenance infliximab: A randomized controlled trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kang, B.(1)*;Moon, J.S.(2);Lee, Y.J.(3);Kim, M.J.(4);Choe, B.H.(1);Ko, J.S.(2);Park, J.H.(3);Choe, Y.H.(4);
Created: Friday, 14 July 2023, 10:43 AM
DOP84 Crohn’s disease modifies the DNA methylome of human adipose-stem cells, which is only partially re-established in remission
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Serena1, M. Millan2, M. Ejarque1, A. Saera-Vila1, D. Monfort-Ferré1, M. Bautista3, M. Menacho3, M. Martí4, E. Espin4, J. Vendrell1, S. Fernández-Veledo1

Created: Thursday, 30 January 2020, 10:12 AM
DOP84: Colonic CD4+ T cell senescence is implicated in the progression of experimental colitis in aged mice
Year: 2024
Source: ECCO'24 Stockholm
Authors: Zhang, Yang
Created: Tuesday, 30 April 2024, 5:03 PM
DOP84: Crohn’s Disease modifies the DNA methylome of human adipose-stem cells, which is only partially re-established in remission
Year: 2020
Source: ECCO'20 Vienna
Authors: Carolina Serena
Created: Tuesday, 23 June 2020, 5:40 PM
DOP84: Crohn’s Disease modifies the DNA methylome of human adipose-stem cells, which is only partially re-established in remission
Year: 2020
Source: ECCO'20 Vienna
Authors: Carolina Serena
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP84: Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn’s Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study
Year: 2021
Source: ECCO'21 Virtual
Authors: D'Haens, G.(1);Baert, F.(2);Danese, S.(3);Kobayashi, T.(4);Loftus Jr., E.V.(5);Sandborn, W.J.(6);Dornic, Q.(7);Lindner, D.(7);Kisfalvi, K.(8);Marins, E.G.(8);Vermeire, S.(9)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP84: IBD-related hospitalization and surgery rates in biologic-naïve patients with IBD treated with vedolizumab versus other biologics: Results from a long-term, prospective, observational study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sebastian, S.(1)*;Siegel, C.(2);Siegmund, B.(3);Zhou, J.(4);Jones, S.(5);Adsul, S.(4);Louis, E.(6);
Created: Friday, 14 July 2023, 10:43 AM
DOP84: Nationwide incidence and prevalence of paediatric inflammatory bowel disease in Scotland 2015–2017 demonstrates the highest paediatric prevalence rate recorded worldwide
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Burgess*1,2, P. Henderson1,2, I. Chalmers3, R. Harris4, R. Hansen4, R. Russell4, D. Wilson1,2

Created: Friday, 22 February 2019, 9:41 AM
DOP84: Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn’s Disease: Post-hoc analysis from the phase 3 study FORTIFY
Year: 2022
Source: ECCO'22
Authors: Irving, P.M.(1);Abreu, M.(2);Axler, J.(3);Gao, X.(4);Torres, J.(5);Neimark, E.(6);Song, A.(7);Wallace, K.(7);Kligys, K.(8);Berg, S.(8);Liao, X.(7);Panaccione, R.(9);
Created: Friday, 11 February 2022, 3:52 PM
DOP85 The role of fibroblasts in the pathogenesis of Crohn’s disease-associated fistulas and in mesenchymal stem cell therapy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R.S. Bruckner1, M.C. Barnhoorn1, H. Mei2, S.M. Kiełbasa2, T.J. Harrijvan1, S.K. Hakuno1, J.J. van der Reijden1, A.E. van der Meulen-de Jong1, L.J.A.C. Hawinkels1

Created: Thursday, 30 January 2020, 10:12 AM
DOP85: An anti-fibrotic role for eosinophils in a DSS colitis RAG-/- and an in vitro co-culture model
Year: 2024
Source: ECCO'24 Stockholm
Authors: Jacobs, Inge
Created: Tuesday, 30 April 2024, 5:03 PM
DOP85: Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study
Year: 2021
Source: ECCO'21 Virtual
Authors: Vavricka, S.R.(1);Greuter, T.(2);Cohen, B.L.(3);Reinisch, W.(4);Steinwurz, F.(5);Fellmann, M.(6);Guo, X.(7);Lawendy, N.(7);Paulissen, J.(8);Peyrin-Biroulet, L.(9)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP85: Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. Two year results of the STRIDENT Randomised Controlled Trial.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Schulberg, J.(1,2)*;Hamilton, A.(1,2);Wright, E.K.(1,2);Holt, B.(1,2);Lovett, G.(1,2);Sutherland, T.(2,3);Ross, A.(1);Vogrin, S.(2);Kamm, M.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
DOP85: Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn’s Disease and inadequate response to risankizumab maintenance therapy
Year: 2022
Source: ECCO'22
Authors: Baert, F.J.(1);Atreya, R.(2);Kakuta, Y.(3);Long, M.(4);Roblin, X.(5);Neimark, E.(6);Song, A.(6);Wallace, K.(6);Kingys, K.(6);Mallick, M.(6);Liao, X.(6);Lim, A.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP85: Rising depression and antidepressant use amongst inflammatory bowel disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Blackwell*1, S. Saxena2, C. Alexakis1, E. Cecil2, A. Bottle2, I. Petersen3,4, M. Hotopf5, R. Pollok1

Created: Friday, 22 February 2019, 9:41 AM
DOP85: Rising depression and antidepressant use amongst Inflammatory Bowel Disease patients
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Jonathan Blackwell
Created: Tuesday, 28 May 2019, 3:32 PM
MDT, Pharmacist, Psychologist, Psychological co-morbidity, Psychological co-morbidity
Files: 1
DOP86 An IFN-STAT1-MLKL axis drives programmed necrosis of Paneth cells in Crohn’s ileitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. HARTMANN1, B. Siegmund2, C. Weidinger2, C. Becker1, M.F. Neurath1, C. Günther1

Created: Thursday, 30 January 2020, 10:12 AM
DOP86: Corticosteroid-sparing effects of ustekinumab therapy for Ulcerative Colitis through 3 years: UNIFI long-term extension
Year: 2021
Source: ECCO'21 Virtual
Authors: Scherl, E.J.(1);Rowbotham, D.S.(2);Danese, S.(3);Sandborn, W.J.(4);Miao, Y.(5);Zhang, H.(5);Abreu, M.T.(6);Panaccione, R.(7);Afif, W.(8);Hisamatsu, T.(9);Leong, R.W.(10);Arasaradnam, R.P.(11);Sands, B.E.(12);Marano, C.(5)
Created: Wednesday, 2 June 2021, 4:12 PM